Jitai Medicine (METiS) is a biotechnology company that uses artificial intelligence to drive drug delivery and drug discovery. It combines advanced technologies like artificial intelligence, machine learning, and quantum simulation to achieve more effective design of innovative delivery materials, drug candidate selection and formulation design, "programmable nucleic acid drug" development, and nucleic acid delivery design.
Regenerative Bio is the world's first anti-aging biotechnology company driven by artificial intelligence and cloud supercomputing, Regenerative Bio combines AI pharmaceutical-related technologies with biology to explore ingredients, formulations and therapies with anti-aging effects, and solve the problems caused by aging.
Curve Health is senior care without walls. It is a platform that's reduced patient transfers from Skilled Nursing Facilities (SNFs) to Emergency Departments by 50%+, Curve advances connected senior care by bridging the silos that hinder healthcare delivery today; enabling physicians to remotely care for patients in SNFs, at home, in ambulances or wherever they may be. Curve combines telemedicine, a health information exchange, predictive analytics, and smart billing into a single platform, resulting in higher quality care + significant return on investment while ensuring the most seamless patient experience.
GreenLight Biosciences is an integrated life sciences company with a cutting-edge platform to deliver higher-quality RNA at a lower cost and more quickly than was ever before possible. GreenLight develops RNA products and collaborates with industry leaders to advance vaccine development, pandemic preparation, crop management, plant protection and support the health of bees and other pollinators.
Virtue Diagnostics is an innovative IVD company focused on infectious disease, cancer, and chronic diseases.
Xbiome is the first AI pharmaceutical company in China that specializes in intestinal micro-ecology. It is based on intestinal micro-ecology and relies on AI technology to accurately and personally manage the gut health of 1.3 billion people. The company uses artificial intelligence to analyze patient and donor intestinal (gut) flora to more quickly develop effective pharmaceuticals.
Jitai Medicine (METiS) is a biotechnology company that uses artificial intelligence to drive drug delivery and drug discovery. It combines advanced technologies like artificial intelligence, machine learning, and quantum simulation to achieve more effective design of innovative delivery materials, drug candidate selection and formulation design, "programmable nucleic acid drug" development, and nucleic acid delivery design.
METiS Therapeutics is a biotechnology company that aims to drive therapies in a wide range of disease areas by integrating drug discovery and delivery with AI, machine learning, and quantum simulation.
Abogen Biosciences is a discovery stage biotechnology company focuses on developing nucleic acid-based (RNA and DNA) therapeutics for treatment of cancer and infectious diseases.
Generate Biomedicines is a biotechnological company focusing on creating breakthrough medicines. It pioneers in the field of Generative Biology, a revolutionary approach to drug development that allows them to program protein-based modalities for the first time. Generate Biomedicines has proved that its machine-learning platform can generate new biological molecules with therapeutic value, accelerating the drug discovery process.
Signet Therapeutics is a biopharmaceutical startup focusing on developing innovative targeted cancer drugs using novel disease models.
Ailurus Biotechnology is the biocomputer company that establishes the architecture and language to program biology. The company's operating system is designed to allocate resources and manage processes. By providing cloud-accessible bio-computation infrastructures, Ailurus Biotechnology aims to make biotech as efficient as lT.
Etern is developing small molecule drugs for protein liquid-liquid phase separation, using the LLPS platform for AI-enabled target discovery, high-throughput screening, and optimization. This could open new treatment strategies for major diseases.
XtalPi is a pharmaceutical technology company that is reinventing the industry’s approach to drug research and development with its Intelligent Digital Drug Discovery and Development (ID4) platform. Through its tightly interwoven quantum mechanics, artificial intelligence, and high-performance cloud computing algorithms, the ID4 platform enables pharmaceutical companies to increase their efficiency, accuracy, and success rate at critical stages of drug R&D. By accelerating the pace of drug discovery and development, XtalPi aims to contribute to a healthier society worldwide. Founded in 2014 by a group of quantum physicists at MIT, XtalPi has since grown into an elite team of researchers with multi-disciplinary expertise in physics, chemistry, pharmaceutical R&D, and algorithm design. XtalPi has received much recognition for its cutting-edge technologies, its innovative solutions, and the breadth of potential applications of its offerings across the pharmaceutical value chain, which has allowed it to gain industry approval and establish strategic partnerships with several top international pharmaceutical companies.
Bota Biosciences (Bota Bio) is a global industrial biotechnology company connecting biological design to scale-up manufacturing to accelerate shifts to sustainable living. Bota has built an integrative bioengineering platform, to develop and implement efficient, eco-friendly, and cost-effective biomanufacturing technologies. Committed to its mission, Bota established its own pilot plant and manufacturing facility, affirming its dedication to offering scalable industrial solutions and market-ready products. This infrastructure strengthens support for customers and partners across industries such as nutrition, food, personal care, and animal health. Powered by a dynamic, multidisciplinary team, Bota Bio channels biotech innovations to create a global impact. The company's Series B financing has surpassed $100 million, bringing its aggregate funding to $145 million, with investment from notable strategic and financial investors, including Hong Shan Capital, Matrix Partners, and BASF Ventures.
Zhishan Weixin Biotechnology
Series A in 2021
Zhishan Weixin Biotechnology integrates gene-drug research and development to treat genetic and neurodegenerative diseases. The company focuses on the research and development and subversive production of rAAV gene drugs. Zhishan Weixin's therapeutic areas cover blood diseases, rare diseases, and other disease areas.
Application of artificial intelligence, multi-omics data, and digital disease models to enable the next era of target & biomarker R&D.
Medbanks Network Technology provides data processing services to the healthcare industry. It develops an oncology database of clinical and professional medical services using information collected from hospitals. It was founded in 2014 and is based in Beijing.
Xbiome is the first AI pharmaceutical company in China that specializes in intestinal micro-ecology. It is based on intestinal micro-ecology and relies on AI technology to accurately and personally manage the gut health of 1.3 billion people. The company uses artificial intelligence to analyze patient and donor intestinal (gut) flora to more quickly develop effective pharmaceuticals.
Nordson Chuanglian was founded in 2014 and is based in Beijing. Nordson has been deeply involved in the pharmaceutical sector since its inception. It has a self-developed intelligent business operation platform that cuts into the core business links of pharmaceutical companies and helps pharmaceutical companies achieve higher efficiency under the premise of compliance. It is based on the world's leading semantic understanding and deep learning algorithms.
XtalPi is a pharmaceutical technology company that is reinventing the industry’s approach to drug research and development with its Intelligent Digital Drug Discovery and Development (ID4) platform. Through its tightly interwoven quantum mechanics, artificial intelligence, and high-performance cloud computing algorithms, the ID4 platform enables pharmaceutical companies to increase their efficiency, accuracy, and success rate at critical stages of drug R&D. By accelerating the pace of drug discovery and development, XtalPi aims to contribute to a healthier society worldwide. Founded in 2014 by a group of quantum physicists at MIT, XtalPi has since grown into an elite team of researchers with multi-disciplinary expertise in physics, chemistry, pharmaceutical R&D, and algorithm design. XtalPi has received much recognition for its cutting-edge technologies, its innovative solutions, and the breadth of potential applications of its offerings across the pharmaceutical value chain, which has allowed it to gain industry approval and establish strategic partnerships with several top international pharmaceutical companies.
Prescryptive Health is a digital health company focused on improving the prescription drug market.
Big Health is a digital therapeutics company that operates a digital healthcare portal to offer fully-automated and highly personalized digital therapeutics and behavioral programs for mental health issues. Its portal offers an online personalized medicine-care and prepares a sleep improvement program in consultation with medical professionals that enable individuals to overcome their sleep-related disorders in an efficient manner.
Cyted focuses on providing digital diagnostic infrastructure to drive the earlier detection of disease. Our technologies use artificial intelligence and novel biomarkers to unlock clinical insight and improve patient outcomes. Cyted's mission is to revolutionise diagnostic methods to build a world where disease is prevented rather than treated.
Xbiome is the first AI pharmaceutical company in China that specializes in intestinal micro-ecology. It is based on intestinal micro-ecology and relies on AI technology to accurately and personally manage the gut health of 1.3 billion people. The company uses artificial intelligence to analyze patient and donor intestinal (gut) flora to more quickly develop effective pharmaceuticals.
Taimei Technology is a Digital Innovator in the R&D and Life Science Industry. Taimei has developed an industry-leading, successfully deployed integrated digital platform that is dedicated to clinical research with in-depth insights into drug R&D, pharmacovigilance, marketing & sales and market access. Our unified digital platform integrates advanced AI, big data, cloud computing and mobile Internet technologies to provide innovative solutions to the industry stakeholders across the full product life cycle. Taimei Technology is building the infrastructure for the future of the life science industry to accelerate product launches, improve quality, enhance drug safety, improve drug accessibility and reduce the medical burden on patients and providers.
IM Therapeutics develops personalized immunotherapeutic drugs for autoimmune diseases based on the genetic risk attributed by human leukocyte antigen (HLA) genes. Their lead candidate drug is an oral drug that starves the autoimmune process in type 1 diabetes (T1D) by blocking DQ8 on specific immune cells. Their goal is to preserve pancreatic beta-cell function and maintain normal insulin production in at-risk and early-stage patients with type 1 diabetes. They are leveraging Their HLA platform to expand their pipeline beyond T1D, to include drug development for Celiac disease (gluten sensitivity) as well as potential additional autoimmune diseases. It was founded in 2015 and is headquartered in Aurora, Colorado.
ZielBio is an early-stage biotechnology company that identifies novel high-value disease targets and develops therapeutic interventions to improve patient outcomes. Its proprietary drug discovery platform Zielfind combines the power of functional, high throughput screening with large content data analytics to identify high-value targets. They have a promising pipeline of therapies and targets, including lead compound ZB131, a proprietary humanized monoclonal antibody against cell surface plectin (CSP) a cancer target identified through Zielfind. ZielBio was founded in 2011 and is based in Charlottesville, Virginia, United States.
Medannex's goal is to create a first-in-class antibody therapy to improve the lives of people impacted by cancers and autoimmune diseases.
XtalPi is a pharmaceutical technology company that is reinventing the industry’s approach to drug research and development with its Intelligent Digital Drug Discovery and Development (ID4) platform. Through its tightly interwoven quantum mechanics, artificial intelligence, and high-performance cloud computing algorithms, the ID4 platform enables pharmaceutical companies to increase their efficiency, accuracy, and success rate at critical stages of drug R&D. By accelerating the pace of drug discovery and development, XtalPi aims to contribute to a healthier society worldwide. Founded in 2014 by a group of quantum physicists at MIT, XtalPi has since grown into an elite team of researchers with multi-disciplinary expertise in physics, chemistry, pharmaceutical R&D, and algorithm design. XtalPi has received much recognition for its cutting-edge technologies, its innovative solutions, and the breadth of potential applications of its offerings across the pharmaceutical value chain, which has allowed it to gain industry approval and establish strategic partnerships with several top international pharmaceutical companies.
Yunhu Health is a Chinese third-party medical testing service platform.Yunhu Technology is a grassroots medical inspection service platform. It mainly sends the inspection samples to the laboratory through the self-built cold chain logistics transportation system. After testing, analysis and review, the test results will be uploaded to the cloud call inspection service cloud platform. Customers can log on to the platform to download and view. The platform also provides accurate inspection services, health management services and value-added services such as inspection report interpretation and disease diagnosis and treatment recommendations to help improve the comprehensive diagnosis and treatment capabilities of primary medical institutions. Recently, according to the arterial network, cloud-based technology, the leader in the Internet service platform of the primary medical industry,
Apic Bio is a gene therapy company that develops treatment options for rare, undertreated neurological and liver diseases. The company is advancing several novel gene therapies to treat Alpha-1 Antitrypsin Deficiency (Alpha-1), genetic Amyotrophic Lateral Sclerosis (ALS), and other CNS diseases.
Founded in September 2014, GeneDock is a national high-tech enterprise dedicated to the development of precision medical data technology. It has the industry-leading experience in building medical data platforms, providing medical, scientific research institutions and enterprises with a comprehensive platform for building data platforms. Pratt & Whitney's precision medical applications use data technology to drive innovation in the health care sector. At present, it has provided group data platform services for dozens of domestic top three hospitals, top industry institutions and enterprises including Southwest Hospital, Xinhua Hospital and Huada Science and Technology; core members are from well-known enterprises such as Alibaba and Huada Gene; Jingwei China, Puhua Capital, Shell Society, Lenovo Star and other well-known investment institutions invest.
Triastek develops 3D printed medicines and the production facilities to manufacture them and has already filed patent applications for its technology.
Taimei Technology is a Digital Innovator in the R&D and Life Science Industry. Taimei has developed an industry-leading, successfully deployed integrated digital platform that is dedicated to clinical research with in-depth insights into drug R&D, pharmacovigilance, marketing & sales and market access. Our unified digital platform integrates advanced AI, big data, cloud computing and mobile Internet technologies to provide innovative solutions to the industry stakeholders across the full product life cycle. Taimei Technology is building the infrastructure for the future of the life science industry to accelerate product launches, improve quality, enhance drug safety, improve drug accessibility and reduce the medical burden on patients and providers.
Etong Health provides healthcare management services. Their services include physical examination, company group examination, personal physical examination, health management, HRD service, physical examination agency, physical examination center, human resources, medicine, medical, and corporate services.
Yunhu Health is a Chinese third-party medical testing service platform.Yunhu Technology is a grassroots medical inspection service platform. It mainly sends the inspection samples to the laboratory through the self-built cold chain logistics transportation system. After testing, analysis and review, the test results will be uploaded to the cloud call inspection service cloud platform. Customers can log on to the platform to download and view. The platform also provides accurate inspection services, health management services and value-added services such as inspection report interpretation and disease diagnosis and treatment recommendations to help improve the comprehensive diagnosis and treatment capabilities of primary medical institutions. Recently, according to the arterial network, cloud-based technology, the leader in the Internet service platform of the primary medical industry,
Apellis Pharmaceuticals is an early-stage biotechnology company focused on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease. The company is leveraging courageous science, creativity, and compassion to deliver life-changing medicines. They aim to develop best-in-class and first-in-class therapies for a broad range of debilitating diseases that are driven by uncontrolled or excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology, and neurology. It was founded in 2008 and headquartered in Waltham, Massachusetts, United States.
Elysium Health offers health products built with science such as dietary supplements and anti-aging drugs. It seeks to solve challenges in health with science, to help people live healthier and longer lives. It works directly with the scientists, clinicians, and health professionals around the world to identify and develop the natural compounds. Its product is a proprietary formulation of two ingredients designed to support long-term well-being at the cellular level.
Advanced Cell Diagnostics (ACD) is a leader in the emerging field of molecular pathology, developing cell- and tissue-based diagnostic tests for personalized medicine. Based in the heart of Silicon Valley, ACD was founded and managed by experienced entrepreneurs in the life science industry.
Mirna Therapeutics, Inc. (Mirna) is a discovery-stage biopharmaceutical research and development company focused on miRNA-directed human oncology therapies. Featuring world-class research capabilities, a strong understanding of miRNA and cancer biology, and an expansive IP portfolio, Mirna Therapeutics is well-positioned to capitalize on the emerging field of miRNA-based therapeutics.
Aduro Biotech is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapies that are designed to harness the body's natural immune system for the treatment of patients with challenging diseases.It was founded in 2000 and headquartered in Berkeley, California.
InSilixa, Inc., headquartered in Sunnyvale, CA, is a multidisciplinary, highly motivated and highly technical team comprised of industry veterans with diverse backgrounds in semiconductor, biotechnology, medicine, and informatics. Founded in 2012, InSilixa is driven by the quest to democratize and drive down the cost of molecular diagnostics worldwide by leveraging its proprietary semiconductor-based CMOS biochip technology. To that end, the company is developing point-of-care (PoC) and near patient platforms for the delivery of low cost, high-performance, and mass-deployable solutions for DNA and protein-based diagnostic testing.
Aduro Biotech is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapies that are designed to harness the body's natural immune system for the treatment of patients with challenging diseases.It was founded in 2000 and headquartered in Berkeley, California.
CellCentric’s primary programme targets a deubiquitinase (DUB) enzyme which is strongly associated with prostate cancer, a leading cause of mortality among men. The target modulates the androgen receptor pathway and can potentially combat the multiple resistance mechanisms seen with recently approved prostate cancer drugs such Xtandi and Zytiga. The programme also has potential clinical utility in non-small cell lung, breast and colon cancer.
Advanced Cell Diagnostics (ACD) is a leader in the emerging field of molecular pathology, developing cell- and tissue-based diagnostic tests for personalized medicine. Based in the heart of Silicon Valley, ACD was founded and managed by experienced entrepreneurs in the life science industry.
Aduro Biotech is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapies that are designed to harness the body's natural immune system for the treatment of patients with challenging diseases.It was founded in 2000 and headquartered in Berkeley, California.
Genocea Biosciences is a biopharmaceutical company which is engaged in developing novel vaccines and immunotherapies to address diseases with significant unmet needs.Its product candidate includes GEN-003 which is an immunotherapy for the treatment of genital herpes as well as it owns pre-clinical immuno-oncology program focused on personalized cancer vaccines. The company focuses on developing vaccines and immunotherapies for unmet needs through its AnTigen Lead Acquisition System, which is used to design vaccines and immunotherapies. Genocea operates its business through the single segment being Developing and Commercializing vaccines.
Developer of proprietary blood-based biomarker tests to transform the management of chronic respiratory diseases. The company is focused on addressing the unmet need for tools to provide a real-time, biological assessment of a patient’s disease state. ProterixBio's products will enable health care providers to better manage their patients and avoid unnecessary hospitalizations, leading to improved outcomes and reduced health care costs. It was founded in 2002 and headquartered in Billerica, Massachusetts.
OriGene Technologies was founded as a research tool company focused on the creation of the largest commercial collection of full-length human cDNAs. It strives to fulfill its mission of supplying everything a researcher needs for gene-based research. Through licensing and selling research materials including genes, proteins, and research tools, it enables critical biological research.
Advanced Cell Diagnostics (ACD) is a leader in the emerging field of molecular pathology, developing cell- and tissue-based diagnostic tests for personalized medicine. Based in the heart of Silicon Valley, ACD was founded and managed by experienced entrepreneurs in the life science industry.
BioVex is a biotechnology company focused on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. Their cancer program, OncoVEXGM-CSF, is a oncolytic vaccine or cancer destroying virus technology that works by replicating and spreading within solid tumors, causing the death of cancer cells while leaving surrounding healthy cells unharmed. The attenuated virus has also been constructed to induce a powerful systemic anti tumor immune response. OncoVEXGM-CSF has now been tested in >110 patients in a broad range of solid tumors including melanoma, head & neck cancer, breast cancer and pancreatic cancer. Both the direct cell killing and systemic immune mediated mechanisms of action of OncoVEX have been clearly validated in the clinic; OncoVEX routinely destroys tumors it is directly injected into and has led to overall disease responses in multiple patients in Phase II testing. Tumors resolved through OncoVEX treatment have not been known to recur.
HD Biosciences Inc. (HDB) is a Shanghai-based biotech company specializing in drug discovery contract research. HDB has developed extensive knowledge and comprehensive technology platforms for drug discovery including assay development, high throughput drug screening, SAR, closed-loop and hit-to-lead biology solutions, as well as natural product-based lead discovery. The Company has signed multiple-year research agreements with clients including Pfizer, Organon and other pharmaceutical and biotech clients and is an indisputable leader in high value-added biology-based drug discovery CRO business in China.